

LISTING OF CLAIMS:

This listing of claims provided below will replace all prior versions and listings of claims in the application.

Please amend the claims as follows:

1. (Currently Amended): A method for treating a host infected with RSV comprising administering an anti-RSV effective amount of a compound of Formula I:



or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

R₁ is selected from the group consisting of -NHC(O)Y, where Y is C₁-C₂₂ alkyl, C₂-C₂₂ alkenyl, and C₂-C₂₂ alkynyl;

R₂ is selected from the group consisting of -OX, where X is C₁-C₂₂ C₁-C₅ alkyl, C₂-C₂₂ C₂-C₅ alkenyl, and C₂-C₂₂ C₂-C₅ alkynyl; and

R₃ is phosphocholine.

2. (Currently Amended): The method of claim 1 wherein Y is and X are independently C₁-C₁₄ alkyl, C₂-C₁₄ alkenyl, or C₂-C₁₄ alkynyl.

3. (Original): The method of claim 1 wherein:


Y is -C₁₀H₂₁; and

X is -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, or -C₁₀H₂₁.


4. (Original): The method of claim 1 wherein Y is -C₁₁H₂₃ and X is C₁-C₅ alkyl.

5. (Currently Amended): The method of claim 1 wherein Y is -C₉H₁₉ and X is C₉-C₁₄ alkyl.


6. (Currently Amended): The method of claim 1, wherein the compound is




3-dodecanamido-2-ethoxypropyl-1-phosphocholine,




3-decanamido-2-ethoxypropyl-1-phosphocholine,




3-decanamido-2-decyloxypropyl-1-phosphocholine,



3-dodecanamido-2-octyloxypropyl-1-phosphocholine,



~~3-dodecanamido-2-dodecyloxypropyl-1-phosphocholine, or~~




3-dodecanamido-2-butyloxy-1-phosphocholine; or a combination thereof.

7. (Original): The method of claim 1 wherein the host is a mammal.

8. (Original): The method of claim 1 wherein the host is a human.

9. (Withdrawn): A method for treating a host infected with RSV comprising administering an anti-RSV effective amount of a compound of Formula II:



or a pharmaceutically acceptable salt or prodrugs thereof,

wherein:

M is C₂-C₄ alkyl;

X₁ is selected from the group consisting of -S-, -O-, -NH-, and -NHC(O)-;

R₂₁ is selected from the group consisting of C₁-C₂₀ straight chain alkyl, C₂-C₂₀ straight chain alkylene containing not more than four double bonds, and aryl;

R₂₂ is selected from the group consisting of C₁-C₂₀ straight chain alkyl, C₂-C₂₀ straight chain alkylene containing not more than four double bonds, and aryl; and

R₂₃, R₂₄, and R₂₅ are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, and isopropyl.

10. (Withdrawn): The method of claim 9 wherein

M is -CH₂CH₂-;

X₁ is -NHC(O)-;

R₂₁ is selected from the group consisting of a C₁-C₁₆ straight chain alkyl and C₂-C₁₆ straight chain alkylene containing not more than one double bond;

R₂₂ is selected from the group consisting of a C₁-C₁₆ straight chain alkyl and C₂-C₁₆ straight chain alkylene containing not more than one double bond; and

R₂₃, R₂₄, and R₂₅ are each independently hydrogen or methyl.

11. (Withdrawn): The method of claim 9 wherein

R₂₁ is selected from the group consisting of C₁-C₁₆ straight chain alkyl and C₂-C₁₆ straight chain alkylene containing not more than one double bond; and

R₂₂ is selected from the group consisting of C₁-C₅ straight chain alkyl and C₂-C₅ straight chain alkylene containing not more than one double bond.

12. (Withdrawn): The method of claim 11 wherein R₂₁ is C₉-C₁₂ alkyl and R₂₂ is C₁-C₁₂ alkyl.


13. (Withdrawn): The method of claim 11 wherein R₂₁ is C₉-C₁₂ alkyl and R₂₂ is C₁-C₅ alkyl.

14. (Withdrawn): The method of claim 11 wherein R₂₁ is C₉-C₁₂ alkyl and R₂₂ is C₈-C₁₂ alkyl.

15. (Withdrawn): The method of claim 9 wherein the host comprises a mammal.

16. (Withdrawn): The method of claim 9 wherein the host comprises a human.

17. (Withdrawn): A method for treating a host infected with RSV comprising administering an anti-RSV effective amount of a compound of Formula III:



or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

Y is selected from the group consisting of -S-, -O-, -NH-, -N(CH₃)-, -NHC(O)-, and -N(CH₃)C(O)-;

R₁ is selected from the group consisting of C₁-C₁₈ alkyl, C₂-C₁₈ alkenyl, C₂-C₁₈ alkynyl, and aryl;

X is a covalent bond or methylene that is optionally substituted with a hydroxyl, C₁-C₂₀ alkyl, -O-(C₁-C₂₀ alkyl), -S-(C₁-C₂₀ alkyl), -C(O)N(C₁-C₂₀ alkyl), C₂-C₂₀ alkenyl, -O-(C₂-C₂₀ alkenyl), -S-(C₂-C₂₀ alkenyl), -C(O)N(C₂-C₂₀ alkenyl), C₂-C₂₀ alkynyl, -O-(C₂-C₂₀ alkynyl), -S-(C₂-C₂₀ alkynyl), or -C(O)N(C₂-C₂₀ alkynyl);

J is a C₁-C₄ alkyl optionally substituted from one to three times with methyl or ethyl; and

R₂, R₃, and R₄ are independently hydrogen or C₁-C₃ alkyl.

18. (Withdrawn): The method of claim 17 wherein:

Y is -NHC(O)-;

R₁ is C₆-C₁₈ alkyl;

X is -C(H)(O-C₁-C₁₈ alkyl)- or -C(H)(O-C₁-C₁₈ alkenyl)-;

J is -CH₂CH₂-; and

R₂, R₃, and R₄ are each methyl.

19. (Withdrawn): The method of claim 18 wherein R₁ is -C₁₁H₂₃ and X is -C(H)(O-C₁-C₅ alkyl)-or -C(H)(O-C₁-C₅ alkenyl)-


20. (Withdrawn): The method of claim 18 wherein R₁ is -C₉H₁₉ and X is -C(H)(OC₂H₅)-

21. (Withdrawn): The method of claim 17 wherein R₁ is -C₉H₁₉ and X is -C(H)(OC₁₀H₂₁)-.

22. (Withdrawn): The method of claim 17 wherein the host comprises a mammal.

23. (Withdrawn): The method of claim 17 wherein the host comprises a human.

24. (Withdrawn and Currently Amended): A method for treating a host infected with RSV comprising administering an anti-RSV effective amount of a compound of Formula IV:



or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

R₁ is selected from the group consisting of C₁-C₁₈ alkyl, C₂-C₁₈ alkenyl, and C₂-C₁₈ alkynyl that is optionally substituted from 1 to 5 times with -OH, -COOH, oxo, amino, or aryl;

X is selected from the group consisting of -NHC(O)-, -N(CH₃)C(O)-, -C(O)NH-, -C(O)N(CH₃)-, -S-, -S(O)-, -(SO₂)-, -O-, -NH-, and -N(CH₃)-;

R₂ is selected from the group consisting of C₁-C₁₄ alkyl, C₂-C₁₄ alkenyl, and C₂-C₁₄ alkynyl that is optionally substituted from 1 to 5 times with -OH, -COOH, oxo, amino, or aryl;

Y is selected from the group consisting of -NHC(O)-, -N(CH₃)C(O)-, -C(O)NH-, -C(O)N(CH₃)-, -S-, -S(O)-, -(SO₂)-, -O-, -NH-, -N(CH₃)-, and -OC(O)-;

R₆ is selected from the group consisting of C₂-C₆ alkyl; C₂-C₆ alkenyl, and C₂-C₆ alkynyl; and

R₃, R₄, and R₅ are independently methyl or ethyl, or R₃ and R₄ together form an aliphatic or heterocyclic ring having five or six ring atoms and R₅ is methyl or ethyl.

25. (Withdrawn): The method of claim 24 wherein:

R₂ is C₁-C₁₄ alkyl, C₂-C₁₄ alkenyl, or C₂-C₁₄ alkynyl;

R₆ is -CH₂CH₂-; and

R₃, R₄, and R₅ are each independently CH₃.

26. (Withdrawn): The method of claim 25 wherein R₂ is C₁-C₅ alkyl or C₂-C₅ alkenyl.

27. (Withdrawn): The method of claim 25 wherein R₁ is C₈-C₁₂ alkyl and R₂ is C₁-C₁₂ alkyl.

28. (Withdrawn): The method of claim 25 wherein R₁ is C₈-C₁₂ alkyl and R₂ is C₁-C₅ alkyl.


29. (Withdrawn): The method of claim 25 wherein R₁ is C₈-C₁₂ alkyl and R₂ is C₈-C₁₂ alkyl

30. (Withdrawn): The method of claim 27 wherein
X is -NHC(O), -N(CH₃)C(O)-, -C(O)NH-, -C(O)N(CH₃); and
Y is -O-, -NH-, or -N(CH₃)-.

31. (Withdrawn): The method of claim 24 wherein the host comprises a mammal.


32. (Withdrawn): The method of claim 24 wherein the host comprises a human.

33. (Withdrawn): The method of claim 24 wherein the compound comprises:




3-dodecanamido-2-ethoxypropyl-1-phosphocholine.

34. (Withdrawn): The method of claim 24 wherein the compound comprises:



3-decanamido-2-ethoxypropyl-1-phosphocholine.

35. (Withdrawn and Currently Amended): A method for treating a host infected with RSV comprising administering an anti-RSV effective amount of a compound of Formula AA-1:



(AA-1)

or a pharmaceutically acceptable salt or prodrug thereof,
wherein:

X¹ is -NHC(O)-;

X² is -O-;

R¹ is -C₁-C₂₂ alkyl;

R² is -C₁-C₂₂ alkyl;

R⁶ is -CH₂CH₂-; and

R³, R⁴, and R⁵ are methyl.

36. (Withdrawn): The method of claim 35, wherein

R¹ is -CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -

CH₂CH₂CH₂CH₂CH₃, -(CH₂)₅CH₃, -(CH₂)₆CH₃, -(CH₂)₇CH₃, -(CH₂)₈CH₃, -

(CH₂)₉CH₃, -(CH₂)₁₀CH₃, -(CH₂)₁₁CH₃, -(CH₂)₁₂CH₃ or -(CH₂)₁₃CH₃; and

R² is -CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -

CH₂CH₂CH₂CH₂CH₃, -(CH₂)₅CH₃, -(CH₂)₆CH₃, -(CH₂)₇CH₃, -(CH₂)₈CH₃, -

(CH₂)₉CH₃, -(CH₂)₁₀CH₃, -(CH₂)₁₁CH₃, -(CH₂)₁₂CH₃ or -(CH₂)₁₃CH₃.

37. (Withdrawn): The method of claim 36, wherein

R¹ is -(CH₂)₈CH₃, -(CH₂)₉CH₃, -(CH₂)₁₀CH₃, -(CH₂)₁₁CH₃; -(CH₂)₁₂CH₃,

or -(CH₂)₁₃CH₃; and

R² is CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -

CH₂CH₂CH₂CH₂CH₃, -(CH₂)₅CH₃, -(CH₂)₆CH₃, or -(CH₂)₇CH₃.

38. (Withdrawn): The method of claim 36, wherein

R¹ is -(CH₂)₅CH₃, -(CH₂)₆CH₃, -(CH₂)₇CH₃, -(CH₂)₈CH₃, -(CH₂)₉CH₃, -(CH₂)₁₀CH₃, -(CH₂)₁₁CH₃, or -(CH₂)₁₂CH₃; and
R² is -(CH₂)₆CH₃, -(CH₂)₇CH₃, -(CH₂)₈CH₃, -(CH₂)₉CH₃, -(CH₂)₁₀CH₃, -(CH₂)₁₁CH₃, -(CH₂)₁₂CH₃, or -(CH₂)₁₃CH₃.

39. (Withdrawn): The method of claim 1, wherein the administering is orally, intravenously, parentally, intradermally, subcutaneously, topically, or by inhalation.